局部治疗联合系统治疗在不可切除肝癌中的研究进展

摘要/Abstract

摘要： 肝癌在我国恶性肿瘤发病率中居第5位,肿瘤相关致死原因中居第2位。大多数肝癌患者待出现特征性症状时病变已属于中晚期并失去最佳手术治疗时机,因此姑息治疗在肝细胞癌的治疗中占核心地位。局部治疗是不可手术切除肝细胞癌（uHCC）患者的主要治疗方案之一,免疫治疗、靶向治疗等系统治疗近年来也取得了实质性进展,但单用介入手段或单药治疗的效果有限,而多种联合治疗方案在临床研究中积极探索并取得了肯定的疗效,为uHCC患者的治疗带来了希望。局部治疗联合系统治疗的新组合预计是中晚期肝癌潜在的治疗模式。现将局部治疗联合系统治疗的研究现状进行综述,旨在为uHCC患者提供更多治疗策略。

关键词: 局部治疗, 系统治疗, 肝细胞癌, 研究进展

Abstract: Liver cancer ranks fifth in the incidence of malignant tumors and second in the causes of cancer-related death in China. Most of the patients have already developed to the middle and late stages when characteristic symptoms appear, have missed the best time for surgery, so palliative therapy plays a central role in the treatment of hepatocellular carcinoma. Locoregional treatment is one of the main therapeutic options for patients with unresectable hepatocellular carcinoma (uHCC), and immunotherapy and targeted systemic therapy have also made substantial progress in recent years, but the effect of interventional therapy alone or monotherapy is limited. Several combination therapy options have been actively explored in clinical studies, with encouraging efficacy and brought hope for the treatment of uHCC patients. Among them,the new combination of locoregional combined with systemic therapy is expected to be a potential therapeutic modality for intermediate and advanced hepatocellular carcinoma. This review provides an overview of the current status of research on locoregional combined with systemic therapy, aim to provide more treatment strategies for uHCC patients.

Key words: Locoregional therapies, Systemic therapies, Hepatocellular carcinoma, Research progress

景聪敏, 张玉宝. 局部治疗联合系统治疗在不可切除肝癌中的研究进展[J]. 肝癌电子杂志, 2024, 11(4): 50-53.

Jing Congmin, Zhang Yubao. Research progress of locoregional therapies combined with systemic therapies in unresectable hepatocellular carcinoma[J]. Electronic Journal of Liver Tumor, 2024, 11(4): 50-53.

参考文献

[1] SUNG H, FERLAY J, SIEGEL R L, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: A Cancer J Clin, 2021, 71(3): 209-249.
[2] CAO W, CHEN H D, YU Y W, et al.Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J, 2021, 134(7): 783-791.
[3] LLOVET J M, MONTAL R, SIA D, et al.Molecular therapies and precision medicine for hepatocellular carcinoma[J]. Nat Rev Clin Oncol,2018,15(10):599-616.
[4] HENDI M, MOU Y P, LYU J M, et al.Hepatic arterial infusion chemotherapy is a feasible treatment option for hepatocellular carcinoma: a new update[J]. Gastrointest Tumors, 2021, 8(4): 145-152.
[5] LLOVET J M, HILGARD P, DE OLIVEIRA A C, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008: 13.
[6] KUDO M, FINN R S, QIN S K, et al.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126): 1163-1173.
[7] LLOVET J M, CASTET F, HEIKENWALDER M, et al.Immunotherapies for hepatocellular carcinoma[J]. Nature Rev Clin Oncol, 2022, 19(3): 151-172.
[8] KAIBORI M, MATSUSHIMA H, ISHIZAKI M, et al.The impact of sorafenib in combination with transarterial chemoembolization on the outcomes of intermediate-stage hepatocellular carcinoma[J]. Asian Pac J Cancer Prev, 2021, 22(4): 1217-1224.
[9] KUDO M, UESHIMA K, IKEDA M, et al.Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial[J]. Gut, 2020, 69(8): 1492-1501.
[10] FU Z G, LI X W, ZHONG J M, et al.Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study[J]. Hepatol Int, 2021, 15(3): 663-675.
[11] KAN X, LIANG B, ZHOU G, et al.Transarterial chemoembolization combined with apatinib for advanced hepatocellular carcinoma: a propensity score matching analysis[J]. Front Oncol, 2020, 10: 970.
[12] 顾杰, 许晨, 周卫忠, 等. TACE联合低剂量阿帕替尼治疗中晚期肝癌的疗效及生存预后分析[J]. 介入放射学杂志, 2022, 31(2): 143-147.
[13] 张晓赟, 朱心睿, 彭伟, 等. 经肝动脉化疗栓塞+仑伐替尼+PD-1单抗在中晚期不可切除肝癌转化切除中的安全性和有效性的前瞻性队列研究:初步报告[J]. 中国普外基础与临床杂志, 2022, 29(1): 39-45.
[14] WU J Y, YIN Z Y, BAI Y N, et al.Lenvatinib combined with anti-pd-1 antibodies plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a multicenter retrospective study[J]. J Hepatocell Carcinoma, 2021, 8: 1233-1240.
[15] CAI M, HUANG W, HUANG J, et al.Transarterial chemoembolization combined with lenvatinib plus PD-1 inhibitor for advanced hepatocellular carcinoma: a retrospective cohort study[J]. Front Immunol, 2022, 13: 848387.
[16] HE M K, LE Y, LI Q J, et al.Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study[J]. Chin J Cancer, 2017, 36(1): 83.
[17] LI Q J, HE M K, CHEN H W, et al.Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase Ⅲ trial[J]. J Clin Oncol, 2022, 40(2): 150-160.
[18] TSAI W L, SUN W C, CHEN W C, et al.Hepatic arterial infusion chemotherapy vs transcatheter arterial embolization for patients with huge unresectable hepatocellular carcinoma[J]. Medicine, 2020, 99(32): e21489.
[19] CHOI J H, CHUNG W J, BAE S H, et al.Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis[J]. Cancer Chemother Pharmacol, 2018, 82(3): 469-478.
[20] HE M, LI Q, ZOU R, et al.Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion[J]. JAMA Oncol, 2019, 5(7): 953-960.
[21] IKEDA M, YAMASHITA T, OGASAWARA S, et al.937P Multicenter phaseⅡ trial of lenvatinib plus hepatic intra-arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma: LEOPARD[J]. Ann Oncol, 2021, 32(Suppl 5): S821-S822.
[22] XU Y J, LAI Z C, HE M K, et al.Toripalimab combined with hepatic arterial infusion chemotherapy versus lenvatinib for advanced hepatocellular carcinoma[J]. Technol Cancer Res Treat, 2021, 20: 15330338211063848.
[23] MEI J, LI S H, LI Q J, et al.Anti-PD-1 immunotherapy improves the efficacy of hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma[J]. J Hepatocell Carcinoma, 2021, 8: 167-176.
[24] HE M K, LIANG R B, ZHAO Y, et al.Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma[J]. Ther Adv Med Oncol, 2021, 13: 17588359211002720.
[25] ZHANG T Q, ZUO M X, GENG Z J, et al.946P Hepatic artery infusion chemotherapy (HAIC) combined with apatinib and camrelizumab for hepatocellular carcinoma (HCC) in BCLC stage C: a prospective, single-arm, phase II trial (TRIPLET study)[J]. Ann Oncol, 2021, 32(Suppl 5): S825.
[26] LEE J J X, TAN S H, HENNEDIGE T P, et al. 947P Updated survival and secondary safety and efficacy analyses from CA 209-678: a phase II open-label single-centre study of Y90-radioembolisation (Y90) in combination with nivolumab in Asian patients (pts) with advanced hepatocellular carcinoma (aHCC)[J]. Ann Oncol, 2021, 32(Suppl 5): S825.